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C3 glomerulopathy describes glomerular pathology
associated with predominant deposition of complement C3
including dense deposit disease and C3 glomerulonephritis.
Familial C3 glomerulonephritis has been associated with
rearrangements affecting the complement factor H–related
(CFHR) genes. These include a hybrid CFHR3-1 gene and
an internal duplication within the CFHR5 gene. CFHR5
nephropathy, to date, occurred exclusively in patients with
Cypriot ancestry, and is associated with a heterozygous
internal duplication of the CFHR5 gene resulting in
duplication of the exons encoding the first two domains of
the CFHR5 protein. Affected individuals possess both the
wild-type nine-domain CFHR5 protein (CFHR512-9) and an
abnormally large mutant CFHR5 protein in which the
initial two protein domains are duplicated (CFHR51212-9).
We found CFHR51212-9 in association with familial C3
glomerulonephritis in a family without Cypriot ancestry.
The genomic rearrangement was distinct from that seen
in Cypriot CFHR5 nephropathy. Our findings strengthen
the association between CFHR51212-9 and familial C3
glomerulonephritis and recommend screening for
CFHR51212-9 in patients with C3 glomerulopathy irrespective
of ethnicity. Since CFHR51212-9 can result from at least
two genomic rearrangements, screening is most readily
achieved through analysis of CFHR5 protein.
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Aberrant regulation of the complement alternative pathway is
associated with C3 glomerulopathy (C3G), a group of
glomerular diseases characterized by predominant comple-
ment C3 deposition. C3G incorporates entities with distinct
EM features: dense deposit disease and C3 glomerulone-
phritis.1 Complement factor H (CFH) is an important
physiological regulator of the complement alternative
pathway, and animal and human models have demon-
strated a strong link between CFH dysfunction and C3G.2
CFH is part of a family that includes the five complement
factor H–related proteins (CFHR1-5). Their contribution to
C3G pathogenesis was first revealed by the demonstration
that a heterozygous CFHR5 mutation was associated with
familial C3G in patients of Cypriot descent (Cypriot CFHR5
nephropathy).3 The mutation resulted in duplication of the
first two protein subunits (termed short consensus repeat
(SCR) domains resulting in a CFHR5 protein with 11
(CFHR51212-9) rather than the normal nine SCR domains
(CFHR512-9). This type of C3G was termed CFHR5 nephro-
pathy. In addition, a novel CFHR3-1 hybrid gene was
associated with familial C3G in a family with Irish
ancestry.4 Here we report the first case of familial C3G
associated with CFHR51212-9 in a family of non-Cypriot
descent. In this family, CFHR51212-9 arose as a consequence of
a genomic rearrangement distinct from that characterized in
Cypriot CFHR5 nephropathy.
RESULTS
A 46-year-old man (index case, III-5, Figure 1) presented
with a several-year history of recurrent intermittent macro-
scopic hematuria, often associated with symptoms of self-
limiting upper respiratory tract infection. There was a family
history of renal impairment (Figure 1); his mother (II-3) was
dialysis dependent following a history of microscopic
hematuria and type 2 diabetes; his maternal uncle (II-4)
had had renal failure attributed to diabetes; and one maternal
cousin (III-2) had been investigated for microscopic
hematuria when 25 years old, was referred for nephrology
review at the age of 45 with reduced estimated glomerular
filtration rate of 51ml/min, reached end-stage renal failure in
2005 when 52, and received a living-related renal transplant
in 2006. The index case’s mother and uncle had not had a
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renal biopsy. His cousin (III-2) had undergone native renal
biopsy in 1998; light microscopy showed mesangial changes,
but no glomeruli were present in the sections used for
immunofluorescence. In conjunction with the clinical find-
ings at the time, the cousin was diagnosed with probable IgA
nephropathy. The cousin (III-2) had received a kidney
transplant from his sister (III-3) in 2006, which was
functioning; a transplant biopsy at 14 months showed
isometric vacuolation only, but there was recent evidence of
deteriorating graft functioning with dipstick hematuria. The
sister (III-6) of the index case had hematuria with
hydronephrosis, and the sister’s daughter (IV-1) had episodic
macroscopic hematuria. The family originates from a single
county in the western part of the United Kingdom and have
no known Cypriot ancestry. No other family members suffer
from diabetes mellitus. No evidence of immune deficiency
has been identified in any family members.
The index case had a protein:creatinine ratio of
15mg/mmol (normal range o45mg/mmol) and estimated
glomerular filtration rate of 66ml/min per 1.73m2. Serum
complement C3 and C4 levels were normal on three
occasions (C3 1.45, 1.42, 1.26 (normal range 0.65–1.65 g/l);
C4 0.25, 0.25, 0.24 (normal range 0.16–0.6 g/l)). Complement
hemolytic (CH50) and alternative pathway activity (AP50)
assays were in the normal range on two occasions. CFH and
complement factor I levels were normal. C3 nephritic factor,
measured using a commercial assay (The Binding Site,
Birmingham, UK), and anti-CFH antibodies were negative.
Renal biopsy contained 10 glomeruli, one of which showed
tuft collapse and thickening of Bowman’s capsule, whereas
the others were normal by light microscopy (Figure 2c).
Immunohistochemistry showed granular C3 on glomerular
capillary walls (Figure 2a). There was no staining for
immunoglobulin A (IgA), IgG, or IgM. Electron microscopy
showed segmental sub-endothelial and intra-membranous
electron-dense deposits (data not shown). This suggested
immunoglobulin-independent complement activation sec-
ondary to a complement alternative pathway abnormality.
We retrospectively reviewed the native and transplant
biopsies of the patient’s cousin (III-2). The native kidney
showed electron-dense deposits on electron microscopy,
similar in morphology to those in cases of CFHR5
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Figure 1 | Pedigree with familial C3 glomerulopathy demonstrating segregation of renal disease with mutant CFHR5 protein. CFHR,
complement factor H related.
Figure 2 | Renal biopsy images. (a) Complement C3 staining in renal
biopsy from index case (III-5). Granular C3 reactivity along the
glomerular capillary walls is present. No staining for immunoglobulin
A (IgA), IgG, or IgM was seen (data not shown). (b) Glomeruli with
negative immunoperoxidase staining for negative control. (c) Light
microscopy showing a periodic acid–Schiff–stained glomerulus from
the index case (III-5). The glomerulus has a normal appearance
by light microscopy. (d) Representative electron microscopic
appearances of native renal biopsy of III-2 demonstrating elongated
sub-endothelial (long arrows) and mesangial (short arrow) electron-
dense deposits.
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nephropathy in Cypriot patients (Figure 2d).3 Although
immunostaining was not done on the cousin’s native kidney
biopsy, transplant renal biopsy 14 months after transplantation
showed both C3 staining on immunofluorescence and
segmental sub-endothelial and intra-membranous electron-
dense deposits on EM. There were no extremely osmiophilic
deposits typical of dense deposit disease. The biopsy findings
were therefore consistent with C3 glomerulonephritis in the
native kidney with recurrence in the transplant, and were
similar to those of the index case and the reported Cypriot
CFHR5 nephropathy biopsies.
In view of the clinical similarities to CFHR5 nephropathy,
we analyzed CFHR5 in the index case. Serum western blotting
for CFHR5 revealed an abnormally large CFHR5 protein in
addition to the normal CFHR5 protein (Figure 3a). The
aberrant band was identical in size to that seen in a Cypriot
patient with CFHR5 nephropathy (Figure 3a, lane 2 positive
control). No coding or splice site mutations were detected on
sequencing the CFHR5 gene. Copy number variation across
the CFHR5 gene (ChromGRCh37:1:196946067–196979404:1)
demonstrated three copies of CFHR5 exons 2 and 3, a finding
identical to that seen in CFHR5 nephropathy previously
(Supplementary Figure 1 online).3 Long-range genomic
polymerase chain reaction (PCR) and sequencing within
this area demonstrated a genomic breakpoint within CFHR5
intron 3 at coordinate 196957850 (nucleotide¼A, CFHR5
intron 3), which linked to CFHR5 intron 1 at coordinate
196949652 (nucleotide¼G, CFHR5 intron 1) with an
intervening ACT triplet (Figure 3b). This breakpoint is close
to but distinct from that seen in Cypriot CFHR5 nephropathy
(Supplementary Figure 2 online). We next designed a
genomic PCR that incorporated primers, which enabled
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Figure 3 | Characterization of the abnormal CFHR5 protein in the pedigree. (a) Western blot of serum with a polyclonal anti-human
CFHR5 antibody. Both the normal CFHR5 protein and an abnormal higher-molecular-weight protein were detected in the index case and the
serum of affected family members. (b) Schematic representation and chromatogram showing genomic breakpoint. The ACT sequence is
common to both introns 1 and 3. The abnormal genomic amplicon was generated using the forward primer in intron 3 (green arrow,
50-TATTGGCTGTGGGTTTGTCA-30) and the reverse primer in intron 1 (red arrow, 50-TGACTGATCACTTATATCACAGTTGG-30). The breakpoint is
4583 bp into CFHR5 intron 3 (A of ACT¼ 4584), where the sequence switches to CFHR5 intron 1 at 2797 (A of ACT¼ 2798). (c) Screening for the
genomic breakpoint by polymerase chain reaction. The 337-bp amplicon is amplified from the wild-type CFHR5 gene. If the intronic breakpoint
is present, a 239-bp amplicon is generated. CFHR, complement factor H related.
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amplification of both the wild-type and mutated locus.
Using this PCR and serum CFHR5 western blotting
(where serum was available), we screened available family
members (Figure 3c). This showed that the two members
with biopsy-proven renal disease (Figures 1 and 3; III-2 and
III-5) harbored the CFHR51212-9 mutation in heterozygosity.
To determine whether CFHR51212-9 segregated with renal
disease in the pedigree, we performed dipstick urinalysis
from all available consenting family members. We defined
microscopic hematuria, with or without macroscopic hema-
turia, proteinuria, or impaired estimated glomerular filtration
rate, as clinical evidence of renal involvement. CFHR51212-9
was present in heterozygosity in all eight members with
abnormal urinalysis (Figures 1 and 3c; III-2, III-5, III-6,
III-8, III-9, III-12, and IV-1 and IV-3) and one member
with no urinalysis available (IV-2), but was absent in the
three members with normal urinalysis (III-10, III-11, and
III-13).
DISCUSSION
The clinical characteristics of the nephropathy in this pedigree
were remarkably similar to Cypriot CFHR5 nephropathy: the
typical presentation was with microscopic and intermittent
macroscopic hematuria, and renal disease was more severe in
affected males.5 We identified an abnormal CFHR51212-9 in
this kindred identical to the aberrant CFHR5 protein found
in Cypriot CFHR5 nephropathy: an internal duplication of
SCRs 1 and 2 is caused by duplication of exons 2 and 3 on
the CFHR5 gene (CFHR5 exon 1 encodes a leader peptide
resulting in exon 2 coding SCR1, and exon 3 encoding
SCR2).6 The CFHR51212-9 segregated with renal involvement.
The demonstration of familial C3 glomerulonephritis
associated with CFHR51212-9 in a demographically unrelated
family with a mutation distinct from that described in Cypriot
CFHR5 nephropathy strengthens the association of the
abnormal CFHR51212-9 and C3G. Although this does not
prove causation, it supports the need for a greater
understanding of the pathogenic role of CFHR51212-9.
CFHR5 is a member of the CFH family of proteins
encoded in the regulators of complement activation gene on
chromosome 1.7 CFHR1, CFHR2, and CFHR5 have recently
been shown to form homodimers and heterodimers in a
head-to-tail configuration via common dimerization
domains within SCR1 and SCR2.8 The dimerization of
CFHR1, CFHR2, and CFHR5 may enhance the avidity of
these proteins for ligand in vivo, enabling them to
competitively antagonize CFH and function as complement
deregulators.8 The duplication of SCR1 and SCR2, as seen in
CFHR51212-9, would theoretically result in the formation of
trimers or higher-order complexes. The larger complexes
could have enhanced ligand avidity and ability to antagonize
CFH. Consistent with this, purified CFHRs from a patient
with CFHR51212-9 are more potent in complement deregu-
lation in vitro than healthy controls.8 This pheno-
menon could apply in vivo particularly where spatial
density of C3 is low or when blood flow rate across the site
of complement activation is high, such as within the kidney.8
We speculate that CFHR5 nephropathy is a result of a failure
of CFH to regulate C3 activation along the glomerular
basement membrane owing to enhanced CFH deregulation
by CFHR51212-9; however, this requires demonstration
in vivo. The deregulation hypothesis could also explain the
protective effect of a CFHR3-1 deletion in IgA nephropathy.9
Fewer CFHRs in serum could lead to less CFH deregulation
enabling tighter control of complement activation and
inflammation. The reason male patients with mutant
CFHR51212-9 seem to have more aggressive clinical renal
disease remains unclear and warrants further investigation.
Our data demonstrate that an abnormal CFHR5 protein
should be looked for in patients with C3G irrespective of
Cypriot ancestry and particularly if there is a family history.
One approach would be to screen for abnormal CFHR5
protein by serum analysis and then proceed with genetic
interrogation of the CFHR locus. This is because we now
know that at least two distinct intronic breakpoints within the
CFHR5 gene can cause the same mutant CFHR5 protein and
C3G. Conversely, protein analysis relies on the fact that the
mutant protein is distinguishable from the wild-type protein
by mass so would not detect an abnormal CFHR5 protein
containing the same number of domains as wild-type CFHR5.
Although never reported, if this scenario were suspected, a
combination of protein analysis and detailed genetic inter-
rogation would be needed to identify the mutation. In
summary, the increasing association between abnormal CFHR
proteins and C3G4,5,10 indicates that variation across this
locus should be looked for in familial C3G.
MATERIALS AND METHODS
The study was conducted according to the Declaration of Helsinki.
Informed consent was obtained from all participants.
Genetic analysis of CFHR5
Exon sequencing of CFHR5 was performed in the index case (III-5).
Amplicons that targeted the exons and at least 50 bp of contiguous
intronic sequence were amplified by PCR using primers (available
on request) designed using the Primer3 software (primer3.source
forge.net). Sequencing reactions were performed using BigDye
Terminator 3.1 Cycle Sequencing Kit (Life Technologies, Paisley,
UK). Both PCR and sequencing reaction products were purified
using Edge Biosystems Gel Filtration plates (Life Technologies). The
sequence was run on a 3730 DNA Analyzer (Life Technologies) and
analyzed using the Sequencer DNA sequencing analysis software.
Genomic DNA was analyzed using the Multiplex Ligation-
Dependent Probe Amplification P236-A1 kit according to the
manufacturer’s instructions (MRC Holland, Amsterdam, The
Netherlands, www.mlpa.com). Assay readings were validated using
samples from individuals with known copy-number variation across
the CFH-CFHR locus. TaqMan probe HS03382618_cn at position
chr1:196952738 (Applied Biosystems, Paisley, United Kingdom
www.appliedbiosystems.com) was additionally used to validate
copy-number variation across the CFHR5 gene. To detect the intro-
nic breakpoint by PCR using genomic DNA, we used the following
primers: 50-TATTGGCTGTGGGTTTGTCA-30, 50-GAATTTTAGA
CCCATATCCCTGAT-30, and 50-TGACTGATCACTTATATCACAG
936 Kidney International (2014) 85, 933–937
c l in i ca l inves t iga t ion N Medjeral-Thomas et al.: Non-Cypriot familial CFHR5 nephropathy
TTGG-30. The 50-TATTGGCTGTGGGTTTGTCA-30 and 50-GAATT
TTAGACCCATATCCCTGAT-30 pair amplify the 337-bp wild-type
amplicon, whereas 50-TATTGGCTGTGGGTTTGTCA-30 and 50-TG
ACTGATCACTTATATCACAGTTGG-30 pair amplify a 239-bp
amplicon if the intronic breakpoint is present. PCR was performed
using Qiagen HotStar Taq DNA polymerase (Qiagen, Manchester,
UK) with 10 ng of genomic DNA according to the manufacturer’s
protocol. Both reactions were multiplexed in the same reaction.
Serum analysis of CFHR5
Western blot for CFHR5 was performed using sera from healthy
control and affected individuals. The samples were run on standard
10% sodium dodecyl sulfate polyacrylamide gel electrophoresis
under nonreducing conditions and probed with a rabbit anti-
CFHR5 polyclonal antibody (Abnova, Taipei City, Taiwan, cat. no.
H30081494-DO1P).
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SUPPLEMENTARY MATERIAL
Figure S1. Copy number variation assay using genomic DNA from
the index case and wild type control using multiplex ligation-
dependent probe assay (MLPA).
Figure S2. Comparison of the intronic breakpoint reported in this
pedigree with that reported in CFHR5 nephropathy in individuals
with Cypriot ancestry.
Supplementary material is linked to the online version of the paper at
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